Fund Your Lung Disease Breakthroughs: Up to $40.6M!
Summary
Seeking innovative institutions to conduct Phase II clinical trials for novel lung disease therapies, aiming to revolutionize patient care. This grant offers significant funding for research with the potential to change clinical management of cardiopulmonary disorders from sleep.
Eligibility
Full Description
Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits grant applications from institutions/organizations to conduct proof-of- concept Phase II clinical trials that test a novel intervention for a lung disease or a cardiopulmonary disorder from sleep that have the potential to significantly change clinical management. In addition, each application must include at least one ancillary study tightly related to the clinical question. Mechanism of Support.
This FOA will utilize the NIH cooperative agreement (U01) grant mechanism. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit up to $40,600,000 (total costs) over 4 years. It is anticipated that up to two awards will be made for each of 3 receipt dates for a total of four to six awards.